1. Scrip
  2. >>Leadership

Getting Women On Boards: LifeSci Advisors' After-Party Mission Is Valued - But Achieving Results Is Hard

 
• By Eleanor Malone

LifeSci Advisors has thrown its back into getting more women on boards, and its efforts have been praised. However, with just 13 women placed in a year and a half, the task is not an easy one.  

SC1803_Annual Report_94009225_1200.jpg
can the boardroom's historic gender bias be overcome? • Source: Shutterstock

The public condemnation of LifeSci Advisors' employment of female models at its now-notorious cocktail party during the J.P. Morgan conference of 2016 led to the Damascene conversion of founding partner Mike Rice. Turning his back on sexist social events, Rice formed an alliance with venture capitalist Kate Bingham after she co-authored a public rebuke to the biotech communications advisory firm. He is now committed to promoting women's representation in biotech boardrooms.

Scrip caught up with Rice and Bingham to find out what LifeSci Advisors has achieved since it gave up recruiting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.